Search 

Novartis Oncology profile

 A business unit within the Novartis Group, Novartis Oncology delivers a broad range of innovative therapies and practical solutions that help change the way patients live with cancer and blood disorders. Glivec® (imatinib) is an oral treatment for multiple rare diseases including forms of Philadelphia-chromosome positive (Ph+) chronic myeloid leukemia (CML) and Kit (CD117)-positive gastrointestinal stromal tumors (GIST). Tasigna® (nilotinib) is approved for Ph+ CML adult patients resistant to or intolerant to at least one prior therapy. Afinitor® (everolimus) is indicated for patients with advanced renal cell carcinoma whose disease has progressed on or after treatment with vascular endothelial growth factor-targeted therapy. Zometa® (zoledronic acid) is indicated for the prevention of skeletal-related events in patients with advanced malignancies involving bone. Zometa also treats hypercalcemia of malignancy. Femara® (letrozole) is approved for adjuvant treatment of hormone receptor positive early breast cancer as well as for extended adjuvant treatment of hormone receptor positive early breast cancer after five years of initial tamoxifen therapy. It is also approved for several uses in certain postmenopausal women with advanced breast cancer. Sandostatin® LAR® (octreotide) helps control symptoms, such as severe diarrhea and flushing, associated with functional gastroenteropancreatic neuroendocrine tumors. It is also approved for the treatment of acromegaly. Exjade® (deferasirox) is approved to treat iron overload in a broad range of patients receiving ongoing blood transfusions. Novartis Oncology has a robust pipeline that utilizes recent discoveries in molecular genomics, rational drug design and state-of-the-art drug discovery technologies.

Partnering strategy

Novartis Oncology is seeking to license or acquire targeted therapeutic approaches to cancer treatment, with a particular interest in projects that have demonstrated Proof-of-Concept in human trials.

The Ono Pharmaceutical Group, in keeping with our philosophy of "Dedicated to Man's Fight against Disease and Pain," has always striven to serve as an R&D-oriented international pharmaceutical company.  In this endeavor we have placed our emphasis on creating innovative medicines that meet international requirements.  In addition to its own original research and development efforts, Ono has been very activly seeking a in-licensing opportunity from companies inside and outside Japan.

ORCHID, in conjunction with its Indian R&D arm, USA drug discovery subsidiary, Bexel Pharmaceuticals Inc, and USA affiliate, Diakron Pharmaceuticals Inc, has new Drug Discovery programs in therapeutic areas of metabolic disorders, cardio-vascular, oncology, inflammation and anti-infectives.
It brings forth a rich pipeline of NCEs for out-licensing and recently received a milestone for an ongoing anti-infective collaboration with MERCK.
Orchid Chemicals & Pharmaceuticals Ltd. (ORCHID), an Indian Pharmaceutical company, of global standing and innovation is fuelling growth through R&D of novel small molecules and new pharmaceutical products backed by scientific, technical and manufacturing competencies and global intellectual property management.
ORCHID operates in business domains of APIs, finished dosage forms (Generics), New Drug Discovery(NCE), & Custom Research & Manufacturing Services (crams), while pursuing biotechnology based green chemistry initiatives and is assessing entry into Bio-Pharmaceuticals (bio-betters).
Orchid continues to expand its patent technologies, new chemical entities/product and services through various business propositions.

Fully Integrated Pharmaceutical Operations

Purdue provides partner companies with extensive expertise in discovery, clinical development, project management, regulatory affairs, manufacturing, marketing, and sales. A dedicated Alliance Management function ensures that every dimension and detail involved in our collaborations gets the attention required. Purdue has regulatory expertise and experience in gaining approval from the U.S. Food and Drug Administration (FDA). Our national U.S. sales and marketing organization has the critical mass and know-how to commercialize new products quickly and effectively.

Purdue Pharma and its independent associated companies (including the Mundipharma/Napp companies) have a presence in more than 30 countries and a staff of more than 5,000.  Each of these international companies is a leader within their respective market for key therapeutic areas.

Purdue has long-standing expertise in pain management and has transformed clinical practice to better serve the needs of patients with pain. We have conducted extensive pharma industry research into the development of analgesics that provide safe and effective pain relief to patients. We work extensively with physicians, opinion leaders, and patient advocacy groups to ensure that pain is appropriately recognized and treated.

Purdue and Shionogi & Co., Ltd., one of Japan’s largest research-based pharmaceutical companies, are collaborating on the discovery and development of new, non-opioid pain medications to treat pain. The research, which targets cellular receptors known to modulate pain responses, is being conducted jointly at Purdue’s research center in Cranbury, New Jersey, and Shionogi’s laboratories in Osaka, Japan.

Purdue has an exclusive U.S. licensing and co-promotion agreement with Labopharm Inc. of Laval, Canada for Ryzolt® (tramadol HCl extended-release tablets), an extended release formulation of tramadol.

Purdue has an exclusive license and collaboration agreement with Transcept Pharmaceuticals, Inc. to commercialize Intermezzo® (zolpidem tartrate sublingual tablet), a product for one type of insomnia.

Additionally, Purdue Pharma L.P. and its independent company, Mundipharma International Corporation Limited, entered into a global partnership with Infinity Pharmaceuticals, Inc. to advance the research, development, and commercialization of Infinity’s discoveries and early clinical programs in oncology (outside the United States) and neuropathic pain (worldwide).

Purdue’s licensing strategy seeks to identify late-stage products within the following therapeutic areas:

• Pain management – both non-opioids and opioids
• Sleep disorders
• Gastrointestinal disorders

At Roche we focus on developing medicines and diagnostics that will help patients live longer, better lives.

We strive to address unmet medical needs through excellence in science – from early detection and prevention of diseases to diagnosis, treatment and treatment monitoring.

Roche Partnering is dedicated to finding the best advances in modern medicine that strengthen the R&D portfolio. Together with external partners, Roche aims to bring new medicines to patients as quickly as possible. Partnering is the doorway to every part of the Roche organisation – from scientists to life cycle teams to the highest levels of management.